Lobbying Relationship

Client

Bausch Health Companies Inc., f/k/a Valeant Pharmaceuticals International, Inc.

More records

Lobbying firm

KING & SPALDING LLP

More records

  • Implementation of Drug Quality and Security Act (DQSA) of 2013

Duration: to

General Issues: Health Issues

Spending: about $50,000 (But it's complicated. Here's why.)

Agencies lobbied since 2017: Food & Drug Administration (FDA), House of Representatives

Related Foreign Entities: Valeant Pharmaceuticals International, Inc. (Laval H7L 4A8, CAN); contribution to lobbying: $0; ownership 100%

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
Allison F. Kassir Staff, Rep. McHale, OSD/DOD & House Armed Services Committee
David Farber n/a
Lisa Dwyer n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Q2 Report
Q1 Report
Q4 Report
Amendment
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page